1. Covering the Cover Gastroenterology
Anson W. Lowe, Richard H. Moseley 
Gastroenterology 
Volume 145, Issue 4, Pages (October 2013)
DOI: /j.gastro
Copyright © 2013 AGA Institute Terms and Conditions

2. Figure 1
Actuarial probability of survival free of relapse defined as a CDAI score >175 in patients treated with azathioprine and placebo.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2013 AGA Institute Terms and Conditions

3. Figure 2
Electron micrographs (EM) with the presence of microvillous inclusions (arrows) in the CDC42 KO mice (iii) compared with the heterozygote controls (i). (ii, iv) Labeling for the apical protein alkaline phosphatase.
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2013 AGA Institute Terms and Conditions

4. Figure 3
Combination treatment of NA808 with PEG-IFN or direct-acting antiviral agents exhibits robust anti-HCV activity in chimeric mice with humanized liver. (A−D) Median change from baseline of serum HCV-RNA over the 14-day monotherapy or combination therapy of NA808 (5 mg/kg/d, intravenously) with PEG-IFN (A: 30 μg/kg/twice weekly, subcutaneously), RO-9187 (B: 1000 mg/kg/d, orally), HCV-796 (C: 100 mg/kg/d, orally), or telaprevir (400 mg/kg/d, orally) and/or HCV-796 (D). (E) HCV-RNA levels in livers of HCG9-infected chimeric mice at the end of each treatment. Error bars = SD. (∗P < .05).
Gastroenterology  , DOI: ( /j.gastro )
Copyright © 2013 AGA Institute Terms and Conditions